Health professionals' attitudes to depot injection antipsychotic medication: a systematic review

Published on Jun 1, 2010in Journal of Psychiatric and Mental Health Nursing2.952
· DOI :10.1111/J.1365-2850.2010.01550.X
Claude Besenius2
Estimated H-index: 2
,
David Clark-Carter21
Estimated H-index: 21
(Staffordshire University),
Peter Nolan28
Estimated H-index: 28
(Staffordshire University)
Sources
Abstract
Healthcare professionals are key providers of information about antipsychotic medication and may have a significant influence on the decisions that service users make about how their medication is delivered. This systematic review aimed to explore health professionals’ attitudes and beliefs towards antipsychotic depot medication. A systematic search of AMED, BNI, CINAHL, EMBASE, HEALTH BUSINESS ELITE, HMIC, MEDLINE and PsycINFO was carried out, as well as hand searches of journals and citation searches. Studies were selected if the terms ‘attitudes/beliefs’ and ‘depot/ injection’ were included in the title or abstract, if health professionals were participants in the study and if original data were included. The search strategy produced 131 papers. Eight relevant studies were then selected for the review. They included six cross-sectional surveys and two qualitative studies. It was shown that the research carried out is still very sparse. Depots are seen as old fashioned, stigmatizing, causing side effects and being costly, and they are often not prescribed because of a presumed adherence to oral medication. More research needs to be carried out to further explore these issues, to look at the role of non-medical prescribers and explore the relationship between health professionals’ attitudes and those of service users.
📖 Papers frequently viewed together
References31
Newest
#1Maxine X. PatelH-Index: 29
#2N. de Zoysa ('KCL': King's College London)H-Index: 5
Last. Anthony S. DavidH-Index: 132
view all 4 authors...
Some clinicians believe that antipsychotic depot injections are unacceptable to patients. This cross-sectional study investigated patients' attitudes regarding antipsychotics, and included within-participant comparisons. Two hundred and twenty-two out-patients with schizophrenia/schizoaffective disorder completed the Drug Attitude Inventory (DAI-10), scales on insight, side effects and treatment preferences. Formulation preference was associated with current medication formulation: depots were p...
Source
#1Maxine X. PatelH-Index: 29
#2F. K.K. YeungH-Index: 3
Last. Anthony S. David ('KCL': King's College London)H-Index: 132
view all 4 authors...
Psychiatric nurses' attitudes to depots have only been explored in the UK. We conducted a cross-sectional attitudinal study for Hong Kong psychiatric nurses and also conducted international comparisons for nurses' views about depots. A pre-existing UK questionnaire on clinicians' attitudes and knowledge regarding depots was updated for the present study. Participants were 98 psychiatric nurses who attended an academic meeting. The majority of respondents had positive views regarding their role i...
Source
#1Maxine X. PatelH-Index: 29
#2Nicole de Zoysa ('KCL': King's College London)H-Index: 10
Last. Anthony S. DavidH-Index: 132
view all 4 authors...
Background: Antipsychotic depot medications improve medication adherence by reducing covert nonadherence, but some clinicians believe that they are unacceptable to patients. This cross-sectional study investigated patients' perspectives on factors influencing adherence to antipsychotics, from both those taking depots and those taking tablets in ongoing voluntary outpatient care. The study is novel in also encompassing such factors as injection phobia and perceived coercion regarding medication i...
Source
Little has been written on the subjective experiences of people who receive depot injectionsin the community. The authors of this paper have identified distinct gaps in the literature interms of the views of service users regarding this particular intervention. Existing studiestend to focus upon the side effects of depot neuroleptic medication and the attitudes ofCommunity Mental Health Nurses (CMHNs) towards administering depot medication andissues of compliance and non-compliance. Mental health...
Source
#1Lizheng Shi (Tulane University)H-Index: 30
#2Haya Ascher-SvanumH-Index: 38
Last. Stephen R. MarderH-Index: 99
view all 6 authors...
Objective: Investigators compared patient characteristics and antipsychotic use patterns between individuals with schizophrenia treated in usual care with first-generation depot antipsychotics and those treated with oral antipsychotics (first- or second-generation or both). Methods: Analyses used data from the U.S. Schizophrenia Care and Assessment Program, a large, prospective study of treatment for schizophrenia conducted July 1997 through September 2003. Participants were assessed at enrollme...
Source
#1Harris Nr (Manchester Mental Health and Social Care Trust)H-Index: 2
#2Karina Lovell (University of Manchester)H-Index: 58
Last. J. C. Day (LJMU: Liverpool John Moores University)H-Index: 1
view all 3 authors...
Pharmacological relapse prevention treatment for people with schizophrenia can last for years if not the person's lifetime. The attitude mental health practitioners (MHPs) hold regarding this treatment can have profound effects on service users' decisions related to treatment. The small number of studies focusing on this issue concentrates on the use of ‘depot’ preparations. To develop a validated inventory to assess the attitudes of MHPs towards treatment and evaluate the attitudes of a sample ...
Source
#1Gary Remington (U of T: University of Toronto)H-Index: 85
#2Jean Kwon (U of T: University of Toronto)H-Index: 1
Last. Bruce K. Christensen (U of T: University of Toronto)H-Index: 48
view all 6 authors...
Abstract Compliance with antipsychotic treatment is a well-recognized concern in the ongoing management of individuals with schizophrenia. The present investigation incorporated the Medication Event Monitoring System (MEMS®) to evaluate compliance in a group of outpatients ( N = 52) with schizophrenia or schizoaffective disorder. Evaluating compliance as a dichotomous variable and using a threshold of 80%, the rate of noncompliance as measured by MEMS® was 52%, considerably higher than self-repo...
Source
#1Stephan Heres (LMU: Ludwig Maximilian University of Munich)H-Index: 13
#2Johannes HamannH-Index: 29
Last. Stefan LeuchtH-Index: 106
view all 4 authors...
Background: Since 2002, a second-generation depot antipsychotic has been available that potentially combines the advantages of depot administration and the favorable aspects of the so-called "atypical" antipsychotics. Nevertheless, long-acting injectable formulations are seldom prescribed in the treatment of schizophrenia. Method: We surveyed 350 psychiatrists at an international conference as to their reasons for not prescribing a first- or second-generation depot antipsychotic for their patien...
Source
#1Diana O. Perkins (UNC: University of North Carolina at Chapel Hill)H-Index: 95
#3Robert M. Hamer (UNC: University of North Carolina at Chapel Hill)H-Index: 66
Last. T. SharmaH-Index: 9
view all 14 authors...
Abstract Background Many patients recovering from a first psychotic episode will discontinue medication against medical advice, even before a 1-year treatment course is completed. Factors associated with treatment adherence in patients with chronic schizophrenia include beliefs about severity of illness and need for treatment, treatment with typical versus atypical antipsychotic and medication side effects. Method In this 2-year prospective study of 254 patients recovering from a first episode o...
Source
#1Jeffrey A. Lieberman (Columbia University)H-Index: 161
#2T. Scott StroupH-Index: 66
Last. John K. Hsiao (NIH: National Institutes of Health)H-Index: 49
view all 12 authors...
background The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared with that of older agents has been incompletely addressed, though newer agents are currently used far more commonly. We compared a first-generation antipsychotic, perphenazine, with several newer drugs in a double-blind study. methods A total of 1493 patients with schizophrenia were recruited at 57 U.S. sites and randomly assigned to receive olanzapine (7.5 to 30 mg per day), perphenazine (8 to ...
Source
Cited By22
Newest
#1Georgios Alevizopoulos (UoA: National and Kapodistrian University of Athens)H-Index: 1
#2Maria Nystazaki (UoA: National and Kapodistrian University of Athens)H-Index: 3
Source
Source
#1Maxine X. Patel ('KCL': King's College London)H-Index: 29
#2Nawal Bent-Ennakhil (Lundbeck)H-Index: 4
Last. Stephan Heres (TUM: Technische Universität München)H-Index: 19
view all 7 authors...
BACKGROUND: Prescription rates for long-acting injectable (LAI) antipsychotic formulations remain relatively low in Europe despite improved adherence over alternative oral antipsychotic treatments. This apparent under-prescription of LAI antipsychotics may have multiple contributing factors, including negative mental health practitioner attitudes towards the use of LAIs. METHODS: The Antipsychotic Long acTing injection in schizOphrenia (ALTO) non-interventional study (NIS), conducted across seve...
Source
#1Sandeep GroverH-Index: 60
#2Swapnajeet SahooH-Index: 16
Last. Aseem MehraH-Index: 12
view all 3 authors...
PURPOSE/BACKGROUND: Despite proven benefits of long-acting injectables (LAIs), these are frequently underused by the psychiatrists. Accordingly, this study aimed to explore the perceptions of psychiatrists toward the use of LAI antipsychotics in their routine clinical practice. METHODS/PROCEDURE: An online e-mail survey was conducted by using Survey Monkey platform. RESULTS: A total of 622 psychiatrists with a mean age of 41 years who were in psychiatric practice for approximately 14 years parti...
Source
#1Giovanni Ostuzzi (University of Verona)H-Index: 15
#2Maria Angela Mazzi (University of Verona)H-Index: 21
Last. Corrado BarbuiH-Index: 73
view all 26 authors...
BACKGROUND: For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predominantly to chronic and severe patients, as a last resort when other treatments failed. Recently, a broader and earlier use of LAIs, particularly second-generation LAIs, has been emphasized. To date, few studies attempted to frame how this change in prescribing took place in real-world practice. Therefore, this study aimed to describe the clinical features of patients prescribed with LAIs, and to...
Source
#1Olufunmilola Abraham (University of Pittsburgh)H-Index: 10
#2Michelle N. Myers (University of Pittsburgh)H-Index: 1
Last. Tanya J. Fabian (University of Pittsburgh)H-Index: 10
view all 5 authors...
Abstract Background The use of Long-Acting Injectable (LAI) antipsychotic medications has increased for patients with Serious Mental Illness (SMI). Care coordination for this population is complex, and pharmacist involvement may improve and support long-term medication adherence and patient outcomes. Objectives (1) Examine pharmacists' role in addressing care coordination and adherence challenges for patients taking Long-Acting Injectable (LAI) antipsychotics; and (2) explore patients' medicatio...
Source
Evidence supports the use of long-acting injectable (LAI) antipsychotics in the treatment and prevention psychosis, but these formulations remain under-used in the UK. Overall, LAIs offer many advantages and the advent of second-generation LAIs increased interest in injectables as these newer drugs offer similar benefits to their oral equivalents. LAIs should be one of the options discussed with patients requiring long-term treatment.
Source
Aims Three-monthly injections of paliperidone palmitate (PP-3M) represent a new and recently introduced long-acting antipsychotic therapeutic option. This review focuses on available data relating to the efficacy and safety of PP-3M and its position in the current therapeutic scenario.
Source
#1Alfredo Carlo Altamura (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)H-Index: 29
#2Andrea Fagiolini (UNISI: University of Siena)H-Index: 56
Last. Alessandro Rossi (University of L'Aquila)H-Index: 71
view all 5 authors...
Corrispondenza A. Altamura • E-mail: carlo.altamura@unimi.it; A. Fagiolini • E-mail: andreafagiolini@gmail.com; S. Galderisi • E-mail: silvana.galderisi@gmail. com; P. Rocca • E-mail: paola.rocca@unito.it; A. Rossi • E-mail: alessandro.rossi@cc.univaq.it Summary Psychosocial therapies play an important role in the treatment of schizophrenia. These therapies are aimed at improving the functioning of the patient in the community, which in turn can lead to clinical improvement, such as reduction in...
Introduction: Mental health workers play different roles in the District Mental Health Service. They differs in professional education skills. Taking care of psychotic patients also include to administrate and observation the medication in practice. There are different experiences in this area. Objectives: To gain knowledge about the practice in the District Mental Health Service according to medication trends. Aims: To gain knowledge and information about the daily practice. Methods: This pilot...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.